-$1.02 EPS Expected for Lumos Pharma, Inc. (NASDAQ:LUMO) This Quarter

Brokerages expect that Lumos Pharma, Inc. (NASDAQ:LUMO) will post earnings of ($1.02) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Lumos Pharma’s earnings, with the lowest EPS estimate coming in at ($1.09) and the highest estimate coming in at ($0.94). Lumos Pharma posted earnings of ($0.65) per share during the same quarter last year, which would indicate a negative year over year growth rate of 56.9%. The firm is expected to issue its next earnings report on Thursday, August 12th.

On average, analysts expect that Lumos Pharma will report full year earnings of ($4.23) per share for the current fiscal year, with EPS estimates ranging from ($4.48) to ($3.77). For the next year, analysts anticipate that the firm will post earnings of ($5.02) per share, with EPS estimates ranging from ($5.77) to ($3.23). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Lumos Pharma.

Lumos Pharma (NASDAQ:LUMO) last announced its quarterly earnings results on Wednesday, May 5th. The company reported ($1.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by ($0.19). Lumos Pharma had a negative return on equity of 10.58% and a negative net margin of 2,053.30%.

Several analysts have issued reports on LUMO shares. Zacks Investment Research lowered shares of Lumos Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday. Jonestrading began coverage on shares of Lumos Pharma in a report on Tuesday, April 13th. They set a “buy” rating and a $34.00 price objective for the company. Finally, Stifel Nicolaus raised shares of Lumos Pharma from a “hold” rating to a “buy” rating and raised their price objective for the stock from $4.00 to $24.00 in a report on Wednesday, March 17th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $31.00.

Several hedge funds and other institutional investors have recently made changes to their positions in LUMO. Foster Group Inc. bought a new position in shares of Lumos Pharma in the fourth quarter worth about $221,000. Bank of New York Mellon Corp bought a new position in shares of Lumos Pharma in the fourth quarter worth about $625,000. Wells Fargo & Company MN raised its stake in shares of Lumos Pharma by 1.1% in the fourth quarter. Wells Fargo & Company MN now owns 117,660 shares of the company’s stock worth $4,202,000 after acquiring an additional 1,268 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Lumos Pharma by 0.9% in the fourth quarter. Renaissance Technologies LLC now owns 308,812 shares of the company’s stock worth $11,028,000 after acquiring an additional 2,700 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Lumos Pharma by 292.0% in the fourth quarter. Northern Trust Corp now owns 12,081 shares of the company’s stock worth $432,000 after acquiring an additional 8,999 shares during the last quarter. 43.79% of the stock is owned by institutional investors.

NASDAQ:LUMO traded down $0.25 during midday trading on Friday, reaching $9.75. The stock had a trading volume of 15,712 shares, compared to its average volume of 53,959. Lumos Pharma has a 1-year low of $9.53 and a 1-year high of $36.72. The firm’s fifty day simple moving average is $11.86 and its 200-day simple moving average is $16.57. The stock has a market capitalization of $81.36 million, a P/E ratio of -3.81 and a beta of 1.69.

Lumos Pharma Company Profile

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency.

Featured Story: What is meant by a buy rating?

Get a free copy of the Zacks research report on Lumos Pharma (LUMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lumos Pharma (NASDAQ:LUMO)

Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.